|Articles|January 18, 2022

Publicis Health Acquires BBK Worldwide

Acquisition to expand clinical trial expertise through technology and patient centricity.

Publicis Health announced the acquisition of BBK Worldwide. BBK enables biotech and pharmaceutical customers to accelerate R&D programs, driving research forward through the integration of patient-centric services and proprietary technology, complementing Publicis Health's existing CTE capabilities.

As part of the acquisition, Publicis Health will acquire BBK Holdings, which in addition to BBK Worldwide, is the parent company of creative advertising agency 320Agency, technology company TCN® Technologies, and solution center RSG Engagement Solution Center. BBK's leadership team and organizational structure will remain in place.

Read more about the acquisition here.


Related to this article

© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.